Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty.

Simple item page
dc.contributor.authorBajpai, Anuragen_US
dc.contributor.authorSharma, Jyotien_US
dc.contributor.authorKabra, Madhulikaen_US
dc.contributor.authorGupta, Arun Ken_US
dc.contributor.authorMenon, P S Nen_US
dc.date.accessioned2002-07-31en_US
dc.date.accessioned2009-05-27T05:07:37Z
dc.date.available2002-07-31en_US
dc.date.available2009-05-27T05:07:37Z
dc.date.issued2002-07-31en_US
dc.description.abstractOBJECTIVE: To evaluate the efficacy of long acting GnRH analogue in improving the auxological outcome of patients with central isosexual precocious puberty (CIPP) and to determine the factors influencing the response. METHODS: Thirty-five patients (30 girls, 5 boys) with CIPP were treated with a long acting GnRH analogue, triptorelin. Final height outcomes and factors affecting treatment were analyzed. RESULTS: Treatment was started at the chronological age (CA) of 6.5 1.8 years in girls and 4.4 1.5 years in boys and continued for a period of 3.7 1.8 years in girls and 6 1.8 years in boys. Follow-up period after discontinuation of treatment was 2.2 0.5 years in girls and 2.6 0.3 years in boys. Treatment led to regression of precocious puberty and reversal of secondary sexual characteristics. There was decline in growth rate reflected by a fall in heightSD of 0.8 0.8 in girls and 2.3 0.9 in boys (p = 0.014), an even greater retardation in bone age (BA) advancement with a decrease in BA-CA of 1.7 1 years in girls and 2.7 1 years in boys and a fall in heightSDBA of 1.5 1.1 in girls and 2.1 1.6 in boys. Final height (149.8 6.9 cm in girls and 161.9 3.9 cm in boys) exceeded projected height at the onset of treatment (143.4 8.3 cm in girls and 154.3 2.7 cm in boys) by 6.4 2.4 cm in girls and 7.6 1.5 cm in boys ( p < 0.001 in both the groups). Factors influencing height gain included age at start of therapy (r = 0.715), BA-CA at the time of initiation of treatment (r = 0.734), heightSDBA at the onset of treatment ( r = 0.566) and the duration of treatment (r = 0.711). Girls treated at an age of less than 6 years (n = 9) had a greater height gain (8.7 1.6 cm versus 5.3 1.9 cm, p < 0.001) and achieved similar final height (148.7 8 cm versus 150.2 6.6 cm) in those treated after this age (n = 21). No side effects of GnRH therapy were observed in the study. CONCLUSION: Long acting GnRH therapy is effective in improving the auxological outcome of patients with CIPP. Maximum benefit is observed in girls with greater bone age advancement treated at a younger age and for a longer duration of treatment. These girls had lower bone age advance at discontinuation of treatment.en_US
dc.description.affiliationDivision of Pediatric Endocrinology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi.en_US
dc.identifier.citationBajpai A, Sharma J, Kabra M, Gupta AK, Menon PS. Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty. Indian Pediatrics. 2002 Jul; 39(7): 633-9en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/8417
dc.language.isoengen_US
dc.source.urihttps://indianpediatrics.neten_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshDelayed-Action Preparations --administration & dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshLuteolytic Agents --administration & dosageen_US
dc.subject.meshMaleen_US
dc.subject.meshPuberty, Precocious --drug therapyen_US
dc.subject.meshTriptorelin --administration & dosageen_US
dc.titleLong-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty.en_US
dc.typeClinical Trialen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Pediatrics